In a nutshell These guidelines aimed to update treatment options for patients with Philadelphia chromosome-positive (Ph+) and negative (Ph-) acute lymphoblastic leukemia (ALL). Some background Acute lymphoblastic leukemia (ALL) represents 75% to 80% of acute leukemia among children and so is the most common form of childhood leukemia. It represents...
Read More
In a nutshell This study aimed to investigate minimal residual disease (MRD) and long-term outcomes of patients with chronic lymphocytic leukemia (CLL) who were treated with venetoclax (Venclexta) and obinutuzumab (Gazyva). This study concluded that this treatment leads to an effective MRD reduction and has...
Read More
In a nutshell This study aimed to investigate the long-term safety and effectiveness of low-dose pegylated (PEG) interferon-α (IFN-α) combined with dasatinib in patients with chronic-phase (CP) chronic myeloid leukemia (CML). This study concluded that this treatment was safe and effective in the long-term in these...
Read More
In a nutshell This study aimed to investigate the risk of infections in patients with blood cancers who were treated with new targeted therapy drugs. This study concluded that a high proportion of these patients experienced severe infections. However, the infection risk was similar to that of chemotherapy. Some background Treatments for...
Read More
In a nutshell This study investigated the effectiveness and safety of fixed-duration treatment with ibrutinib (Imbruvica) plus venetoclax (Venclexta) for patients with previously untreated chronic lymphocytic leukemia (CLL) by using minimal residual disease (MRD) guidance. The data showed that fixed-duration treatment with ibrutinib plus venetoclax was...
Read More
In a nutshell This study evaluated the cardiovascular (CV; heart and blood vessels) side effects in patients with chronic lymphocytic leukemia (CLL) who received acalabrutinib (Calquence) treatment. The data showed that the occurrence of CV side effects with acalabrutinib treatment is very low in patients with CLL. Some background CLL is a type of...
Read More
In a nutshell This study investigated the side effect profiles of different PD-1/PD-L1 inhibitor-based combination therapies. The data showed that PD-1/PD-L1 inhibitors in combination with chemotherapy were associated with a higher risk of treatment-related side effects than with targeted therapy or immunotherapy combinations. Some background...
Read More
In a nutshell This review aimed to explore the effectiveness and safety of gemtuzumab ozogamicin (GO; Mylotarg) in different subtypes of acute myeloid leukemia (AML). This review concluded that this treatment is safe and effective in certain patients with AML. Some background GO is an...
Read More
In a nutshell This review looked at options to preserve future fertility for young people diagnosed with blood cancer. Some background For teens and young adults, blood and bone marrow cancers are one of the most common types of cancer. These include Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), and acute leukemia. Fortunately, blood...
Read More
In a nutshell The review aimed to develop recommendations for stopping tyrosine kinase inhibitor (TKI) therapy in patients with chronic myeloid leukemia CML. Some background Tyrosine kinase inhibitors (TKI) are a type of targeted therapy. TKIs have improved the survival outcomes for patients with chronic myeloid...
Read More
In a nutshell This study assessed the treatment effects of all-trans retinoic acid (ATRA; Vesanoid) and arsenic trioxide (ATO; Trisenox), compared to ATRA with standard chemotherapy on long-term health-related quality of life (HRQoL) in patients with acute promyelocytic leukemia (APL). The data showed better long-term HRQoL measures in patients treated...
Read More
In a nutshell This review aimed to investigate the prognostic value of minimal residual disease (MRD) in patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). This review concluded that MRD is a good predictor of outcomes in these patients. Some background Ph+ ALL is an aggressive type of...
Read More
